ESMO Advanced Course on
Deep Dive in CDK4-6 Inhibitors
Data in Breast Cancer

PROGRAMME
ESMO ADVANCED COURSE PROGRAMME
DEEP DIVE IN CDK4-6 INHIBITORS DATA IN BREAST CANCER
Dubai, United Arab Emirates
20 May 2023

CO-CHAIRS
Giuseppe Curigliano, Italy
Barbara Pistilli, France

SPEAKERS
Ana Bosch, Sweden
Michael Gnant, Austria
Antonio Marra, Italy

LEARNING OBJECTIVES

- Understanding the function and biology of CDK4-6 in malignant breast cancer cells
- Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4-6 inhibition in breast cancer, both in the metastatic setting
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4-6 inhibition
- Providing an outlook of potential integration of CDK4-6 inhibitors in the adjuvant setting
- Discussing clinical cancer cases to integrate use of CDK4-6 inhibitors in clinical practice

ACCREDITATION

The programme of this event has been accredited with 6 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

Novartis | Reimagining Medicine

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
### Saturday, 20 May 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Duration</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:10</td>
<td><strong>Welcome and introduction</strong>&lt;br&gt;Giuseppe Curigliano, IT and Barbara Pistilli, FR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:10-10:45</td>
<td><strong>Session 1 – CDK4-6 inhibitors in breast cancer</strong>&lt;br&gt;Integrating CDK4-6 inhibitors in patients with early HR positive / HER2 negative breast cancer: Successes and failures&lt;br&gt;Michael Gnant, AT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Ongoing clinical studies on CDK4-6 inhibition in early HR positive / HER2 negative breast cancer&lt;br&gt;Barbara Pistilli, FR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Risk stratification in HR positive / HER2 negative early breast cancer: Lessons from neoadjuvant and adjuvant setting&lt;br&gt;Ana Bosch, SE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45-11:15</td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15-12:30</td>
<td><strong>Session 2 – CDK4-6 inhibition in advanced breast cancer</strong>&lt;br&gt;CDK4-6 inhibition in patients with metastatic HR positive / HER2 negative breast cancer: Benefit in endocrine resistant disease&lt;br&gt;Antonio Marra, IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Emerging data on new agents and new combinations in endocrine resistant disease&lt;br&gt;Giuseppe Curigliano, IT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Discussion</strong></td>
<td>15’</td>
<td></td>
</tr>
<tr>
<td>12:30-13:30</td>
<td><strong>Lunch break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-14:45</td>
<td><strong>Session 3 – Research on rational combinations of CDK4-6 inhibitors with targeted agents</strong>&lt;br&gt;Role of CD4-6 inhibitors across enriched molecular subgroup&lt;br&gt;Ana Bosch, SE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>CDK4-6 inhibitors beyond CDK4-6 inhibitors in metastatic setting&lt;br&gt;Giuseppe Curigliano, IT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Discussion</strong></td>
<td>15’</td>
<td></td>
</tr>
<tr>
<td>14:45 -15:45</td>
<td><strong>Session 1 Cont. – CDK4-6 inhibitors in breast cancer</strong>&lt;br&gt;Clinical cases of high-risk patients with early HR positive / HER2 negative early breast candidate to Adjuvant CDK4-6 inhibitors: Balancing efficacy and toxicity&lt;br&gt;Barbara Pistilli, FR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Discussion</strong></td>
<td>15’</td>
<td></td>
</tr>
</tbody>
</table>
15:45-16:15 Coffee Break

16:15-17:05 Workshop Session

Workshop 1 Post CDK4-6 inhibitors in early breast cancer, what to do after relapse in the metastatic setting

25' Presentation of 3 cases by speaker and discussion
25' Discussion

Antonio Marra, IT
Giuseppe Curigliano, IT

17:05-17:20 Synthesis and wrap-up